Aquestive Therapeutics Financials - Benzinga

Aquestive Therapeutics Inc

AQSTNASDAQ

Trade with Public

Trade with Public

$5.34

-0.01-0.19%

At close: Sep 4, 5:00 PM EST

$5.39

0.050.94%

After Hours: Sep 4, 7:31 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Aquestive Therapeutics Financials

Aquestive Therapeutics (AQST) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Aquestive Therapeutics Q2 EPS $(0.18) Misses $(0.12) Estimate, Sales $13.819M Beat $11.418M Estimate

Benzinga Newsdesk

PRO
Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $50.584M Est

Aquestive Therapeutics (NASDAQ:AQST) affirms FY2026 sales outlook from $46.000 million-$50.000 million to $46.000 million-$50.000 million vs $50.584 million estimate.

Benzinga Newsdesk

PRO
Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $48.072M Est

Aquestive Therapeutics (NASDAQ:AQST) affirms FY2026 sales outlook from $46.000 million-$50.000 million to $46.000 million-$50.000 million vs $48.072 million estimate.

Benzinga Newsdesk

PRO
Aquestive Therapeutics Q1 EPS $(0.07) Beats $(0.15) Estimate, Sales $14.446M Beat $10.896M Estimate

Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.15) by 53.33 percent. This is a 70.83 percent increase over losses of $(0.24) per share

Benzinga Newsdesk

Earnings Scheduled For May 13, 2026

Benzinga Insights

Aquestive Therapeutics Q4 Earnings Assessment

Benzinga Insights